Arrowhead Pharmaceuticals Inc (ARWR)

1.73
0.09 4.90
NASDAQ : Health Care
Prev Close 1.82
Open 1.81
Day Low/High 1.70 / 1.85
52 Wk Low/High 3.07 / 9.36
Volume 863.53K
Avg Volume 2.15M
Exchange NASDAQ
Shares Outstanding 74.17M
Market Cap 136.48M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - ARWR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc.

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Provides Response To New Minority Shareholder Announcement

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded to the announcement by Silence Therapeutics plc that it acquired, in the open-market, an equity stake of 6,000,359 Arrowhead shares, representing 8.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 16, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Arrowhead Pharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

ARWR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of Commencement Of A Class Action Involving Arrowhead Pharmaceuticals, Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

Arrowhead Reports Fiscal 2016 Year End Results

Arrowhead Reports Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 fourth quarter and year ended September 30, 2016.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ARWR

ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - ARWR

Rosen Law Firm, reminds purchasers of Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Year End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, December 14, 2016, at 4:30 p.

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Arrowhead Pharmaceuticals, Inc. Investors And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharma Shares Destroyed by Development Announcement

Arrowhead Pharma Shares Destroyed by Development Announcement

The company has seen shares fall 60% since market's close Tuesday.

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneous (subQ) and...

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

Arrowhead Pharmaceuticals Announces Closing Of License And Collaboration Agreement With Amgen

Arrowhead Pharmaceuticals Announces Closing Of License And Collaboration Agreement With Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is pleased to announce that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its...

Interesting ARWR Put And Call Options For January 2019

Interesting ARWR Put And Call Options For January 2019

Investors in Arrowhead Pharmaceuticals Inc saw new options become available today, for the January 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Arrowhead Pharmaceuticals, Inc.